Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.

ABSTRACT:

Purpose

Adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL) is a therapy for metastatic melanoma with response rates of up to 50%. However, the generation of the TIL transfer product is challenging, requiring pooled allogeneic normal donor peripheral blood mononuclear cells (PBMC) used in vitro as "feeders" to support a rapid-expansion protocol. Here, we optimized a platform to propagate TIL to a clinical scale using K562 cells genetically modified to express costimulatory molecules such as CD86, CD137-ligand, and membrane-bound IL-15 to function as artificial antigen-presenting cells (aAPC) as an alternative to using PBMC feeders.

Experimental design

We used aAPC or γ-irradiated PBMC feeders to propagate TIL and measured rates of expansion. The activa

SUBMITTER: Forget MA 

PROVIDER: S-EPMC4199393 | biostudies-literature | 2014 Nov-Dec

REPOSITORIES: biostudies-literature